Development of photoactive Sweet-C 60 for pancreatic cancer stellate cell therapy

Maciej Serda, Matthew J. Ware, Jared M. Newton, Sanchit Sachdeva, Martyna Krzykawska-Serda, Lam Nguyen, Justin Law, Andrew O. Anderson, Steven A. Curley, Lon J. Wilson, Stuart J. Corr

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: Glycoconjugated C 60 derivatives are of particular interest as potential cancer targeting agents due to an upregulated metabolic glucose demand, especially in the case of pancreatic adenocarcinoma and its dense stroma, which is known to be driven by a subset of pancreatic stellate cells. Materials & methods: Herein, we describe the synthesis and biological characterization of a hexakis-glucosamine C 60 derivative (termed 'Sweet-C 60 '). Results: Synthesized fullerene derivative predominantly accumulates in the nucleus of pancreatic stellate cells; is inherently nontoxic up to concentrations of 1 mg/ml; and is photoactive when illuminated with blue and green light, allowing its use as a photodynamic therapy agent. Conclusion: Obtained glycoconjugated nanoplatform is a promising nanotherapeutic for pancreatic cancer. </inline-graphic.

Original languageEnglish (US)
Pages (from-to)2981-2993
Number of pages13
JournalNanomedicine
Volume13
Issue number23
DOIs
StatePublished - Dec 1 2018

Keywords

  • fullerene antibody
  • glycoconjugates
  • pancreatic stellate cells
  • photodynamic therapy
  • [60]fullerene

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Fingerprint

Dive into the research topics of 'Development of photoactive Sweet-C 60 for pancreatic cancer stellate cell therapy'. Together they form a unique fingerprint.

Cite this